Possibly as a result of pressure from the USA, a European Union panel ofexperts last week recommended a relaxation on the rules for import of tallow products, many of which are used in making pharmaceuticals (Marketletter August 18). The USA claimed that an EU ban on imports of animal products due to the outbreak of Creutztfeld-Jacob disease as a result of bovine spongiform encephalopathy in cattle could threaten $100 million worth of US tallow exports.
The committee's opinion, that tallow-derived products could be seen as safe for human use if "the appropriate, validated and scientifically most up-to-date methods" are used in their production, is likely to be become a proposal to EU commissioners.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze